Barry S. Taylor, PhD

Associate Member
Contact
Nicole Scagliola 646.888.3797

About

Dr. Taylor is an Associate Member in the Human Oncology and Pathogenesis Program, Associate Attending Computational Oncologist in the Department of Epidemiology and Biostatistics, and Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology. The goal of his laboratory research is to define the germline and somatic abnormalities that mediate the genesis, progression, and response to therapy of human cancers. His research program lies at the interface of computational and cancer biology, employing translational genomic and functional genetic approaches to identify tumor cell-specific vulnerabilities that can be therapeutically exploited in diverse malignancies. Dr. Taylor’s lab has been involved in many collaborative studies exploring the genomic basic of diverse human cancer types and the development of computational methodologies for cancer genome discovery. His current research centers on exploring the molecular and evolutionary origins of response and resistance to cancer therapy, and defining the mechanisms, serial genetic evolution, and both biological and therapeutic significance of common and rare driver mutations in tumorigenesis. The lab’s overall goal is to capitalize on population-scale and data-driven approaches to accelerate clinical translation in molecularly defined populations of cancer patients.
The Taylor Lab

Education

PhD

Weill Cornell Medical College
New York, New York, USA

Appointments

Computational Oncology, Department of Epidemiology & Biostatistics

Associate Member, Human Oncology and Pathogenesis Program

Associate Professor, Weill Cornell Medical College

Gerstner Sloan Kettering Faculty Member

Affiliations

Associate Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology

Affiliate Member, New York Genome Center

Selected Publications

Jonsson P, …, Taylor BS. Tumor lineage shapes BRCA-mediated phenotypes. Nature, 2019; 571 (7766): 576-579. PMID: 31292550.

Bielski CM, …, Taylor BS. Widespread selection for oncogenic mutant allele imbalance in cancer. Cancer Cell, 2018; 34(5): 852-862. PMID:30393068

Razavi P, …, Solit DB†, Taylor BS†, Baselga J†. The genomic landscape of endocrine resistant advanced breast cancers. Cancer Cell, 2018; 34(3): 427-438. PMC6327853

Bielski CM, …, Taylor BS. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat Genet, 2018; 50(8): 1189-1195. PMID: 30013179

Chang MT, …, Taylor BS. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov, 2018; 8(2): 174-183. PMID: 29247016

Yao Z, …, Taylor BS, Rosen N. Tumors with class 3 BRAF mutants are RAS dependent and sensitive to its inhibition. Nature, 2017; 548(7666): 234-238. PMID: 28783719

Hyman DM, …, Taylor BS. AKT inhibition in solid tumors with AKT1 mutations. J Clin Oncol, 2017; 35(20): 2251-2259. PMC5501365

Chang MT, …, Taylor BS. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nature Biotechnol. 2016; 34(2): 155-63. PMC4744099

Johnson BE, …, Taylor BS†, Costello JF†. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science, 2014; 343(6167): 189-93. PMC3998672

Iyer G, …, Taylor BS†, Solit DB†. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012; 338(6104): 221. PMC3633467

Please visit PubMed or Google Scholar for additional publications